Dyadic reports 2021 year end results and recent company progress

Jupiter, fla., march 29, 2022 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on further improving, applying and deploying its proprietary c1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics today announced its financial results for year end 2021 and highlighted recent company progress.
DYAI Ratings Summary
DYAI Quant Ranking